Minimum 20 minute delay
8/21/2014 7:00:14 AMDUBLIN, Ireland--(BUSINESS WIRE)--Aug. 21, 2014-- Covidien plc (NYSE: COV) today announced that the U.S. Food and Drug Administration (FDA) has approved changes to the manufacturing process for the polytetrafluoroethylene (PTFE) coating on the delivery wire of the company’s Pipeline™ embolization device. …
8/20/2014 4:06:00 PMFacility offers educational resources, research capabilities SÃO PAULO--(BUSINESS WIRE)--Aug. 20, 2014-- Covidien plc (NYSE: COV) today officially opened its Covidien Center of Innovation Brazil (CCI Brazil), further expanding its educational and research capabilities in a key emerging market. The CCI will help educate clinicians in …
8/18/2014 4:05:00 PMLargest directional atherectomy study with independent, core lab analysis demonstrates high limb salvage in patients with critical limb ischemia and strong patency rates in both diabetic and claudicant patients DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 18, 2014-- Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark …
A Partner in Health
Collaborating with physicians and other healthcare professionals, focusing on research and development and maintaining clinical leadership add up to innovative medical solutions that make a difference.
Ensuring ethical interactions with healthcare professionals is vital to the global healthcare environment. Covidien’s Conscientious Collaboration platform is our commitment to open communications about the need to ensure compliant interactions with our customers and partners.
One look. One Covidien. Experience the new unified look of Covidien. Easy-to-use labeling. New outside packaging with the same quality products inside. First-class service and support.